IVUS Study for SV Graft: Y-composite vs Aortocoronary Conduit
Launched by HO YOUNG HWANG · Mar 2, 2021
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
The enrolled patient underwent routine sternotomy, and left internal thoracic artery (LITA) and saphenous vein (SV) are harvested. After harvest, the patient is randomized to Y-composite group or aortocoronary group.
For Y-composite group, SV is anastomosed to LITA as Y-composite fashion. Then, LITA is anastomosed to left anterior descending artery. SV is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posteriori descending artery).
For aortocoronary group, LITA is anastomosed to l...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A patient who is going to receive coronary artery bypass grafting
- • Older than 19 years
- • Coronary artery bypass grafting is going to be performed with left internal thoracic artery and saphenous vein graft
- Exclusion Criteria:
- • Other concomitant procedures (e.g. valve or aorta surgery) is planned
- • Patients with severe comorbidities which limit the life expectancy of them below 1 year (e.g. terminal cancer)
- • Patients whose left internal thoracic artery or saphenous vein is not available due to the low quality, severe injury, or absence of the graft
About Ho Young Hwang
Ho Young Hwang is a distinguished clinical trial sponsor known for its commitment to advancing medical research and innovation. With a focus on developing effective therapeutic solutions, Hwang's team collaborates closely with leading healthcare professionals and research institutions to design and conduct rigorous clinical trials. The organization emphasizes ethical practices, patient safety, and data integrity, ensuring that all studies meet the highest scientific standards. Through its dedication to improving patient outcomes and fostering breakthroughs in treatment, Ho Young Hwang plays a pivotal role in the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Patients applied
Trial Officials
Ho Young Hwang, MD, PhD
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials